ImetelChat

Recent comment section from Nov article very good with “Bridge (our Bridge?) to Rytello” leading the way. I recommend a look.

Not only that but I can't remember a time when the company gave early guidance for the next quarter (they didn't have to do that and probably looked at it as a positive) and was punished for very good numbers. Considering the nascent introduction of Rytello to the market, the numbers look pretty goo...

Good point Ryan. There was no active J code to bolster profits for the fourth quarter. Funny how the market penalized Geron for a 50% income increase from Q3 to Q4. Q1 2025 should give us a more accurate picture.

https://d18rn0p25nwr6d.cloudfront.net/CIK-0000886744/834e66b7-63a7-47b5-8861-e1681d2d6fb6.pdf Note the resurrection of Dr. Teferri’s slide of normalization of fibrotic bone marrow. (10 years old). Clearly they are setting the stage for completion of IMpactMF study. Doubt secondary end points will be...

Jay, am not positive about this but I think the phrase you are referring to could apply to someone like Dr. Rizo, who while no longer employed still served in some capacity that would still allow her to qualify for this program. It does look like this is a straightforward employee stock purchase pla...

LWS, warning flag down. Whether I or anyone else agrees with you or not, this board will not be a forum for your political views. Best to keep them on the YMB.

Unfortunate ain’t it that the company can dangle a carrot but never is under any obligation to tell shareholders when it becomes compost.

1. IMpress has enrolled and is not recruiting, top line data (maybe) next month. 2. TELOMERE ready to go once data from IMpress analyzed and accepted. 3. Clarity for TELOMERE will come (speculation from me based on Dr. B’s ASH presentation) courtesy of Dr. Bruedigam and Lane’s preclinical studies. I...

IMpress trial update: submitted yesterday, posted today. active status, no longer recruiting. no change to primary or study completion dates. 46 patients enrolled.

Somebody correct my work but today I only see three active studies on the clinical trials site sans the high risk MDS/AML (IMpress) study. If the status changed from (eg, recruiting to inactive) that normally would be listed but at least on my screen, it’s just not there. Maybe temporally removed fo...

Your memory is still very much intact, Jay.

Kmall, my read of Dr. Iyer’s 2021 participation in the “investor event” and his subsequent 2022 paper in blood was that the latter was Geron funded and the former a paid, wishy washy event for him. Not surprised his research has taken other directions and would be very surprised, given the lack of s...

FC, to my knowledge there has been nothing new.

Will you guys think less of me if I confess to having no idea who Super Dave was until now? You have opened a whole new world for me! Anytime I feel depressed about Geron’s stock price I will look at another clip.

Kmall, you sure find some interesting stuff. Doubt this podcast happened with out a seed from Geron’s PR dept. Very scripted (you are right about a heavy AI content) and not that well researched (wrong stock price, lots about abandoned or at least inactive programs e.g. age related telomere research...

And then I left this for the poster on YMB:

“Left you a message on Imetelchat. “

And that was rejected too!

I know that YMB doesn’t like caps or short messages but it really is completely worthless

A response to a real question on YMB: Posters question was why the AML study from Dr. Platzbecker showed no responses of note, here’s my reply which was immediately rejected. biopearl 20 seconds ago Hello Mary, the money is in combination therapy with Imetelstat as a keystone and essential part. Thi...

How Health Insurers Racked Up Billions in Extra Payments From Medicare Advantage The Wall Street Journal’s yearlong investigation into Medicare’s private insurers relied on exclusive access to billions of records of Medicare services I can’t post the link since I think you need a subscription to acc...

Mistergern, first patient off to a good start, the others early in the process. Please keep us posted. Be great if any of these patients wanted to post here. If you are posting on the facebook site maybe let them know they can register. Just let me know so I can jump through the necessary hoops. bp